Get the app
US › Healthcare

Immatics NV (IMTX)

US · Healthcare · Biotechnology

$6.73-5.74%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$9.1M
Revenue YoY
+93.0%
Net profit
$-62.5M
EPS
$-0.53
EPS estimate
$-0.43
Net margin
-683.4%

EPS came in at -0.53 against a street estimate of -0.43 — a miss of 23.3%.

Key statistics

Market cap
$1.13B
Forward P/E
0.0
P/B
2.86
Book value
$3.29
EPS (TTM)
$-1.87
52-week high
$12.41
52-week low
$7.02
50-day MA
$8.89
200-day MA
$9.79
Beta
1.36

Analyst view

Analysts rate Immatics NV a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $17.63.

Shareholding

Insiders
15.78%
Institutions
66.82%

Largest institutional holders

FundStake
T. Rowe Price Investment Management,Inc.14.69%
RTW INVESTMENTS, LLC8.50%
Suvretta Capital Management, LLC7.35%
Perceptive Advisors LLC6.82%
Baker Bros Advisors LP6.25%
Jefferies Financial Group Inc4.27%
Vestal Point Capital LP4.06%
Sofinnova Ventures2.41%

Recent filings & reports

DocumentDate
Current report (6-K) · Q3 2026
HEADLINE NUMBERS • Immatics N.V. plans to issue and sell 12,945,916 ordinary shares with a nominal value of €0.01 per share. • It also plans to issu
2026-08-26
Quarterly results (6-K) · Q2 2026
HEADLINE NUMBERS • Q2 2026 revenue from collaboration agreements was €9,144 thousand, up from €4,737 thousand in Q2 2025. • First-half 2026 collabor
2026-08-18
Current report (6-K) · Q2 2026
HEADLINE NUMBERS • Immatics N.V. held its Annual General Meeting of Shareholders on June 18, 2026. • Shareholders approved every item on the meetin
2026-06-18
Current report (6-K) · Q2 2026
HEADLINE NUMBERS • Immatics N.V. adopted the 2026 Stock Option and Incentive Plan to provide equity-based incentives to officers, employees, non-empl
2026-06-02
Quarterly results (6-K) · Q1 2026
HEADLINE NUMBERS • Immatics reported Q1 2026 revenue of €7,612 thousand, down from €18,582 thousand in Q1 2025. • Research and development expenses
2026-05-12
Annual report FY2025 (20-F)
HEADLINE NUMBERS • Fiscal year ended December 31, 2025; financial statements are prepared under IFRS in euros. • Immatics had 134,071,432 ordinary s
2026-03-05
Quarterly results (6-K) · Q3 2025
HEADLINE NUMBERS • Nine-month 2025 revenue from collaboration agreements was €28,505 thousand, down from €99,583 thousand in the restated nine-month
2025-11-17
Quarterly results (6-K) · Q1 20252025-05-13

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Immatics NV — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Data updated 2026-10-19.